

SUNDAY, 16 JULY 2017 – PRE-CONFERENCE SYMPOSIUM

7.00am – 7.30am	Breakfast	7.30am – 8.00am	Breakfast
Symposia	PCFA ANZUP Nurses Symposium: <i>Elements Room</i> Session Chair: <i>Kath Schubach</i> <i>Sponsored by: PCFA and Astellas</i>	Symposia	Translational Research Symposium: <i>Ballroom 3&4</i> Session 1 Chair: <i>Arun Azad</i> <i>Sponsored by: MSD</i>
7.30am – 10.00am	"I wonder...": Transforming ideas into robust clinical questions How many times have you been confronted with a clinical situation and had an idea about improving your patients' care? This workshop is designed to develop your understanding of the language of research, methodology, and give you practical experience in identifying an idea and turning it into a concept outline.	8.00am – 8.05am	Welcome
		8.05am – 8.40am	Molecular sub typing of bladder cancer <i>Peter Black</i>
		8.40am – 9.05am	Catching-up: Opportunities and challenges for kidney cancer biomarkers <i>Craig Gedge</i>
		9.05am – 9.30am	Signatures of Kidney Cancer Identified by Correlated Spectroscopy <i>Sharon Del Vecchio</i>
		9.30am – 10.00am	Targeting metabolic dysfunction induced by ADT in advanced prostate cancer <i>Jennifer Gunter</i>
10.00am – 10.25am	Morning Tea		
10.25am – 10.30am	MDT Masterclass <i>Ballroom 1&2</i> <i>Sponsored by: Janssen</i> <i>Webcast Sponsor: Novartis</i>	Symposia	Session 2 Chair: <i>Anthony Joshua</i>
		10.25am – 10.50am	Integrated preclinical testing using new models of lethal prostate cancer <i>Mitch Lawrence</i>
10.30am – 11.30am	Panel 1: Bladder "There will be Blood" <i>Chair: Andrew Weickhardt</i>	10.50am – 11.15am	Does peri-prostatic fat contain 'the good oil'? <i>Niall Corcoran</i>
		11.15am – 11.40am	Identification of drug response biomarkers in patient-derived prostate explants <i>Lisa Butler</i>
11.30am – 12.30pm	Panel 2: Renal "Back to the Future" <i>Chair: Emma Birch</i>	11.40am – 12.05pm	Towards improved prostate cancer treatment by exploiting microRNAs <i>Luke Selth</i>
		12.05pm – 12.30pm	Targeting the microenvironment in osteoblastic prostate cancer bone metastases <i>Elizabeth Williams</i>
12:30pm – 1:15pm	Lunch		
1.15pm – 2.15pm	Panel 3: Germ Cell "No Country for Old Men" <i>Chair: Ben Tran</i>	Community Engagement Forum "Below The Belt" <i>Elements Room</i> CEF finishes at ~3.45-4pm	
2.15pm – 3.45pm	Panel 4: Prostate "Crouching Tiger Hidden Dragon" <i>Chair: Jeremy Grummet</i>		
3.45pm – 4.00pm	Afternoon Tea		
4.15pm – 6.15pm	Scientific Advisory Committee (SAC) Open Meeting		
6.15pm – 7.15pm	Welcome Reception <i>Sponsored by Amgen</i>		
7.30pm – 10.00pm	Evening Symposium: "The Art of Getting the Science into Best Practice" A primer for detecting scientific baloney Dissemination and uptake of St Gallen recommendations	Session Chair: <i>Ian Davis</i> <i>The Park</i> International Speakers: <i>Robert Lee</i> <i>Silke Gillissen</i> <i>Sponsored by: Astellas, Astra Zeneca, Tolmar</i>	

MONDAY, 17 JULY 2017

7.15am – 8.15am	Breakfast		
7.15am – 7.35am	Translational Breakfast: Session Chair: Ian Vela Immunotherapy development in uro-oncology – new immune targets, biomarkers of response and resistance	<i>Grand Ballroom</i>	Supportive Care Breakfast; Prostate Cancer Survivorship Session Chair: Suzanne Chambers A global perspective and challenges ahead
7.35am – 7.55am	The genomic landscape of BRCA2-mutant prostate cancer	<i>Peter Black</i> <i>Renea Taylor</i>	<i>Elements Room</i> <i>Kevin Stein</i>
7.55am – 8.15am	Bone metastasis in prostate cancer	<i>Peter Croucher</i>	<i>Sponsored by PCFA</i>
8.30am – 10.30am	Plenary: In Best Practice, Great Science is an Art Form Session Chairs: Declan Murphy & Carmel Pezaro		<i>Grand Ballroom</i> <i>Sponsored by: Janssen</i>
8.30am – 8.45am	Official Opening: Professor Helen Zorbas AO, (CEO Cancer Australia) Welcome: Mr Frank McGuire MP (Victorian Parliamentary Secretary for Medical Research) Ian Davis (ANZUP Chair) and Carmel Pezaro (Convener)		
8.45am – 9.05am	Defining deliverables of multiparametric Magnetic Resonance Imaging (mpMRI)/Ultrasound (US) fusion-guided targeted prostate biopsy		<i>Alex Kutikov</i>
9.05am – 9.25am	St Gallen APCCC 2017 – Defining best practice in routine care		<i>Silke Gillessen</i>
9.25am – 9.35am	Question Time 1		
9.35am – 9.55am	Prostate hypofractionation: 4 - 5 weeks or 4 - 5 fractions?		<i>Robert Lee</i>
9.55am – 10.15am	Rehabilitation impacts on HRQoL in advanced cancer pathways		<i>Bente Thoft Jensen</i>
10.15am – 10.30am	Question Time 2		
10.30am – 11.00am	Morning Tea <i>Sponsored by Ferring</i>		
11.00am – 12.10pm	ANZUP in Action Session Chairs: Fritha Hanning, Mark Frydenberg	<i>Sponsored by: ANZUP</i>	<i>Grand Ballroom</i>
11.00am – 11.10am	Update on CAP		<i>Belinda Jago</i>
11.10am – 11.20am	Bladder Cancer Sub-Committee		<i>Dickon Hayne</i>
11.20am – 11.40am	EORTC trials, opportunities for collaboration		<i>Silke Gillessen</i>
11.40am – 12.50pm	Concept Pipeline Update		<i>Subcommittee Chairs</i>
12.50pm – 1.50pm	Lunch <i>Sponsored by Bayer</i>		
1.50pm – 3.10pm	Maximising Potential Session Chairs: Suzanne Chambers, Dickon Hayne	<i>Sponsored by: Ipsen</i>	<i>Grand Ballroom</i>
1.50pm – 2.10pm	Physical prehabilitation in RC pathways		<i>Bente Thoft Jensen</i>
2.10pm – 2.25pm	Exercise medicine: Evidence and implementation in GU oncology		<i>Pruce Cormie</i>
2.25pm – 2.50pm	Prediction of pT0 disease in bladder cancer		<i>Alex Kutikov</i>
2.50pm – 3.00pm	ANZUP TOLMAR 2016 Fellowship recipient report		<i>Arun Azad</i>
3.00pm – 3.10pm	Renal Cell Cancer Sub-Committee		<i>Sponsored by: Ipsen</i> <i>Craig Gedye</i>
3.10pm – 3.30pm	Afternoon Tea		
3.30pm – 4.30pm	Best of the Best Orals Session Chairs: Shahneen Sandhu, George Hruby	<i>Sponsored by: Astellas</i>	<i>Grand Ballroom</i>
3.30pm – 3.40pm	A distinct plasma lipid signature associated with poor prognosis in castration – resistant prostate cancer		<i>Lisa Horvath</i>
3.40pm – 3.50pm	KEYNOTE-045: open-label, phase 3 study of pembrolizumab versus investigators choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer		<i>David Quinn</i>
3.50pm – 4.00pm	Non-invasive selection and monitoring of active surveillance candidates using NMR-based metabolomics: a preliminary investigation of seminal plasma		<i>Matthew Roberts</i>
4.00pm – 4.10pm	Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial		<i>Nicola Lawrence</i>
4.10pm – 4.20pm	Trajectories of distress in female partners of men diagnosed with prostate cancer		<i>Kirstyn Laurie</i>
4.20pm – 4.30pm	Previous ADT duration moderates the exercise response in men with prostate cancer		<i>Dennis Taaffe</i>
4.30pm – 5.00pm	Annual General Meeting (Open to ANZUP members only)		<i>Grand Ballroom</i>
5.00pm – 6.30pm	e-Poster Presentations		<i>Discussants</i>
7.00pm – 11.00pm	Conference Dinner		<i>Sponsored by: Novartis</i> <i>Grand Ballroom</i>

TUESDAY, 18 JULY 2017

7.30am – 8.30am	Emerging Leaders Breakfast Maturing as a Surgeon During a Transformative Time in Urology: When Dogma was Questioned and When Surgical Technique Underwent a Rapid Change The Joy of Good Research	Grand Ballroom <i>Session Chair: Ian Vela</i> <i>Alex Kutikov</i> <i>Liz Kenny</i>
8.45am – 10.00am	Immuno-Oncology in GU Cancers <i>Session Chairs: Andrew Weickhardt, Amy Hayden</i> <i>Sponsored by: Roche</i>	Grand Ballroom
8.45am – 9.00am	Immunotherapy in GU Cancers	<i>David Pook</i>
9.00am – 9.20am	Immunotherapy for non-muscle invasive bladder cancer	<i>Peter Black</i>
9.20am – 9.35am	Combining radiation with immuno-oncology – why and how?	<i>Shankar Siva</i>
9.35am – 9.50am	Managing patient expectations on (and off) immune-oncology agents	<i>Haryana Dhillon</i>
9.50am – 10.00am	Germ Cell Cancer Sub-Committee	<i>Peter Grimison</i>
10.00am – 10.30am	Morning Tea	
10.30am – 12.00pm	Maximising Quality, Minimising Harm <i>Session Chairs: David Pryor, Peter Fong</i> <i>Sponsored by: Tolmar</i>	Grand Ballroom
10.30am – 10.55am	Brachytherapy is the best (old) new technology for radiotherapy delivery	<i>Robert Lee</i>
10.55am – 11.15am	Managing sexuality in prostate cancer patients	<i>Kath Schubach</i>
11.15am – 11.35am	IGCCC Testicular Cancer Update	<i>Silke Gilllessen</i>
11.35am – 11.50am	Managing hypogonadism in testicular cancer survivors	<i>Ada Cheung</i>
11.50am – 12.00pm	QoL & Supportive Care Sub-Committee update	<i>Suzanne Chambers</i>
12.00pm – 12.45pm	Lunch	
12.45pm – 2.00pm	Addressing the Challenges with Trials <i>Session Chairs: Mei Krishnasamy, Leslie Land</i> <i>Sponsored by: Astellas</i>	Grand Ballroom
12.45pm – 1.00pm	Improving clinical trial access to rural, regional and rare cancer patients – A telehealth approach	<i>Sabe Sabesan</i>
1.00pm – 1.10pm	Incorporating geriatric oncology assessment into GU clinical trials	<i>Christopher Steer</i>
1.10pm – 1.25pm	Using trial infrastructure efficiently: platform, factorial, and umbrella trial designs	<i>Andrew Martin</i>
1.25pm – 1.35pm	Does one size fit all?	<i>Richard De Abreu Lourenco</i>
1.35pm – 1.50pm	Has the era of ADT monotherapy come to an end?	<i>Henry Woo</i>
1.50pm – 2.00pm	Prostate Cancer Sub-Committee	<i>Scott Williams</i>
2.00pm – 2.20pm	Afternoon Tea	
2.20pm – 3.40pm	Managing Uncertainties in Practice <i>Session Chairs: Nick Brook, Aneta Suder</i>	Grand Ballroom
2.20pm – 2.40pm	Role of renal biopsy “always, sometimes, or never”	<i>Alex Kutikov</i>
2.40pm – 2.55pm	Genetics testing – implications for advanced prostate cancer	<i>Ainsley Campbell</i>
2.55pm – 3.20pm	Case Discussion: Should we use adjuvant treatments in penile cancer management?	<i>Nathan Lawrentschuk</i>
3.20pm – 3.50pm	Debate: Should Best Practice be About Art or Science?	<i>Facilitator: Joseph Ischia</i> <i>Andrew Kneebone, Suzanne Chambers,</i> <i>Andrew Mant, David Quinn</i>
3.50pm – 4.30pm	Awards and Close Best of the Best Awards	<i>Ian Davis</i> Grand Ballroom <i>Sponsored by: Astellas</i>